###begin article-title 0
CD44s and CD44v6 Expression in Head and Neck Epithelia
###end article-title 0
###begin p 1
Conceived and designed the experiments: OG. Performed the experiments: BM. Analyzed the data: BM OG. Wrote the paper: OG.
###end p 1
###begin title 2
Background
###end title 2
###begin p 3
CD44 splice variants are long-known as being associated with cell transformation. Recently, the standard form of CD44 (CD44s) was shown to be part of the signature of cancer stem cells (CSCs) in colon, breast, and in head and neck squamous cell carcinomas (HNSCC). This is somewhat in contradiction to previous reports on the expression of CD44s in HNSCC. The aim of the present study was to clarify the actual pattern of CD44 expression in head and neck epithelia.
###end p 3
###begin title 4
Methods
###end title 4
###begin p 5
Expression of CD44s and CD44v6 was analysed by immunohistochemistry with specific antibodies in primary head and neck tissues. Scoring of all specimens followed a two-parameters system, which implemented percentages of positive cells and staining intensities from - to +++ (score = %xintensity; resulting max. score 300). In addition, cell surface expression of CD44s and CD44v6 was assessed in lymphocytes and HNSCC.
###end p 5
###begin title 6
Results
###end title 6
###begin p 7
###xml 376 383 364 371 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in situ</italic>
In normal epithelia CD44s and CD44v6 were expressed in 60-95% and 50-80% of cells and yielded mean scores with a standard error of a mean (SEM) of 249.5+/-14.5 and 198+/-11.13, respectively. In oral leukoplakia and in moderately differentiated carcinomas CD44s and CD44v6 levels were slightly increased (278.9+/-7.16 and 242+/-11.7; 291.8+/-5.88 and 287.3+/-6.88). Carcinomas in situ displayed unchanged levels of both proteins whereas poorly differentiated carcinomas consistently expressed diminished CD44s and CD44v6 levels. Lymphocytes and HNSCC lines strongly expressed CD44s but not CD44v6.
###end p 7
###begin title 8
Conclusion
###end title 8
###begin p 9
###xml 318 322 318 322 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">i.e.</italic>
CD44s and CD44v6 expression does not distinguish normal from benign or malignant epithelia of the head and neck. CD44s and CD44v6 were abundantly present in the great majority of cells in head and neck tissues, including carcinomas. Hence, the value of CD44s as a marker for the definition of a small subset of cells (i.e. less than 10%) representing head and neck cancer stem cells may need revision.
###end p 9
###begin title 10
Introduction
###end title 10
###begin p 11
###xml 34 37 34 37 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003360-Aruffo1">[1]</xref>
###xml 240 243 240 243 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003360-Naor1">[2]</xref>
###xml 1003 1006 1003 1006 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003360-Ponta1">[3]</xref>
###xml 249 254 <span type="species:ncbi:9606">human</span>
CD44, the receptor for hyaluronan [1], is encoded by a single gene on chromosome 11p13, but actually represents a polymorphic group of transmembrane glycoproteins owing to extensive alternative splicing and post-translational modifications [2]. The human gene is composed of 19 exons, 10 of which (exons 1-5 and 15-19) are included in the standard form of CD44 termed CD44s. Isoform CD44s is the smallest and most abundant member of this polymorphic and monogenic family of proteins. The remaining exons can be differentially inserted into the mature mRNA via alternative splicing and may in theory give rise to hundreds of protein variants. So far approximately 20 CD44 isoforms were detected in tissues of various origins. In addition to alternative splicing, diversity is added upon varying N- and O-glycosylation sites within the extracellular domain of alternatively spliced products of CD44. In other words, one gene gives rise to a plethora of proteins with potentially discriminative capacities [3].
###end p 11
###begin p 12
###xml 110 113 110 113 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003360-Trowbridge1">[4]</xref>
###xml 450 453 450 453 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003360-Kuhn1">[5]</xref>
###xml 642 645 642 645 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003360-Gunthert1">[6]</xref>
###xml 866 869 866 869 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003360-Okamoto1">[7]</xref>
###xml 870 874 870 874 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003360-Nagano2">[10]</xref>
###xml 1106 1110 1106 1110 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003360-Okamoto2">[11]</xref>
###xml 37 43 <span type="species:ncbi:10090">murine</span>
CD44 was initially identified in the murine lymphoid compartment as a receptor for extracellular matrix (ECM) [4]. Functionally speaking, CD44 is involved in organ integrity through its ability to contact ECM, is signalling active, and serves as a co-receptor for numerous transmembrane proteins such as matrix metalloproteases, members of the ERB family of receptor tyrosine kinases, and the long-known tumour-associated antigen EpCAM (CD326, ESA1) [5]. CD44 was in the focus of molecular oncology in the early 1990s when it was recognized that variants of it, chiefly CD44v6, regulate tumour progression, invasion, and metastasis formation [6]. As has been shown for a number of other receptors, CD44 is dependent on regulated intramembrane proteolysis (RIP) for full activation of its ECM-binding capacity and especially for the induction of signaling properties [7]-[10]. Like the Notch-1 receptor, CD44 is cleaved by ADAM proteases and gamma-secretases to generate an intracellular domain (CD44-ICD), which translocates into the nucleus and fosters transcription of genes from TPA-responsive elements [11].
###end p 12
###begin p 13
###xml 178 182 178 182 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003360-AlHajj1">[12]</xref>
###xml 190 194 190 194 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003360-Dalerba1">[13]</xref>
###xml 206 210 206 210 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003360-Pries1">[14]</xref>
###xml 212 216 212 216 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003360-Prince1">[15]</xref>
###xml 320 321 320 321 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 326 327 326 327 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;</sup>
###xml 333 334 333 334 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 340 344 340 344 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">high</sup>
###xml 353 354 353 354 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 360 364 360 364 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">high</sup>
###xml 383 384 383 384 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;</sup>
###xml 431 438 431 438 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vivo</italic>
###xml 514 515 514 515 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 675 679 675 679 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">i.e.</italic>
###xml 725 729 725 729 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003360-Prince1">[15]</xref>
###xml 731 735 731 735 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003360-Prince2">[16]</xref>
###xml 877 881 877 881 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003360-Prince2">[16]</xref>
###xml 1083 1087 1083 1087 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003360-Pries1">[14]</xref>
###xml 1089 1093 1089 1093 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003360-Prince1">[15]</xref>
###xml 1151 1155 1151 1155 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003360-Shmelkov1">[17]</xref>
###xml 1458 1462 1458 1462 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003360-Soukka1">[18]</xref>
###xml 1463 1467 1463 1467 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003360-VanHal1">[21]</xref>
###xml 417 422 <span type="species:ncbi:9606">human</span>
###xml 460 465 <span type="species:ncbi:10090">mouse</span>
###xml 610 615 <span type="species:ncbi:9606">human</span>
More recently, the attention paid to CD44s was re-fueled by reports on its differential expression on cancer stem cells (CSCs) versus non-tumourigenic carcinoma cells. In breast [12], colon [13], and HNSCC [14], [15], CD44-positivity was a discriminative characteristic of cancer-initiating cells. In these entities CD44+/CD24-, CD44+/EpCAMhigh, or CD44+/Bmi-1high cells but not CD44- cells were able to recapitulate human tumours in vivo in immunocompromised mouse recipients. For the specific case of HNSCC, CD44+ CSCs were reported to represent a minority population of less than 10% of the tumour cells in human primary carcinomas and did hold stem cell-like properties, i.e. self-renewal and pluripotency to some degree [15], [16]. Notedly, the frequency of CSCs in the CD44-positive fraction of HNSCC was one order of magnitude below CSCs from colon or breast carcinomas [16]. Additionally, high-level expression of the transcription factor BMI-1, co-staining with the basal cell marker keratin 5/14, and the lack of involukrin were indicative markers of CSC property in HNSCC [14], [15]. As for the case of the CSC marker CD133 in colon cancer [17], the literature on CD44 expression pattern in HNSCC and its deduced capacity as a CSC marker may appear somewhat controversial. Several research groups described a robust expression of CD44s and/or CD44v6 in head and neck, independently of the malignant state and in a large proportion of tumour cells [18]-[21]. This is clearly in contrast to reports on CD44s as being expressed in less than 10% of HNSCC cells-independently of additional markers used to characterise this minor but highly efficacious tumour cell population.
###end p 13
###begin p 14
###xml 275 280 <span type="species:ncbi:9606">human</span>
In the present study, we have attempted to clarify this issue and assessed the expression of CD44s and of tumour-associated splice variant CD44v6 in epithelia of the head and neck area. Specimens collection included normal epithelia, oral leukoplakia, and full-blown primary human carcinomas of varying grading. In the samples studied, we could not recapitulate a differential expression of CD44s that would characterise carcinoma cells versus normal epithelia. CD44s expression in normal and diseased tissue was in every case above 50% of cells. Although differences between normal and transformed tissue were higher than for the case of CD44s, CD44v6 was not an adequate marker either. Further on, owing to the high incidence of CD44s expression in HNSCC its value as a major CSC marker for this specific entity may need to be thoroughly discussed.
###end p 14
###begin title 15
Results
###end title 15
###begin title 16
CD44 in head and neck epithelia: normal mucosa
###end title 16
###begin p 17
###xml 249 258 249 258 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="pone.0003360.s001">Figure S1</xref>
###xml 585 594 585 594 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="pone.0003360.s002">Figure S2</xref>
###xml 744 752 744 752 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0003360-g001">Figs. 1A</xref>
###xml 757 759 757 759 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0003360-g002">2A</xref>
###xml 1076 1092 1076 1092 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">stratum spinosum</italic>
###xml 1094 1102 1094 1102 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0003360-g001">Figs. 1A</xref>
###xml 1107 1109 1107 1109 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0003360-g002">2A</xref>
###xml 1125 1143 1125 1143 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">stratum granulosum</italic>
###xml 1614 1621 1610 1617 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pone-0003360-t001">Table 1</xref>
###xml 1874 1878 1870 1874 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">i.e.</italic>
###xml 2224 2230 2216 2222 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0003360-g003">Fig. 3</xref>
###xml 486 492 <span type="species:ncbi:10090">murine</span>
Before staining, all samples had been confirmed by two pathologists during routine clinical diagnosis, both after instantaneous section and after embedding. Further on, histopathologic examination was conducted after hematoxylin/eosin staining (see Figure S1 for examples of H/E staining). Samples of normal mucosa (n = 10) were stained with CD44s- or CD44v6-specific antibodies. Cell nuclei were visualised with Mayers hematoxylin. For a control consecutive sections were stained with murine pre-immune serum to test for the specificity of the detection system (examples are shown in Figure S2). In average two thirds of the thickness of normal mucosa samples were positive for CD44s and CD44v6 as assessed with a scale in a light microscopy (Figs. 1A and 2A). Additionally antigen expression was recorded as percentage of CD44s- or CD44v6-positive cells and according to expression levels (- to +++). In normal mucosa a strong (+++) and primarily plasma membrane-associated expression of CD44s and CD44v6 was observed in cells of the basal membrane layer and the suprabasal stratum spinosum (Figs. 1A and 2A). Cells of the stratum granulosum were almost devoid of CD44s and entirely devoid of CD44v6. In opposition to carcinoma samples, a cytoplasmic staining of CD44s and CD44v6 was seen in normal mucosa. This finding may point towards a more efficient shedding of the CD44 ectodomain, although this remains to be shown experimentally. The percentage of CD44s and CD44v6-positive cells within normal epithelia ranged from 60-95% (mean and SEM: 86%+/-3.5%) and 50%-80% (mean and SEM: 66%+/-3.7%), respectively (Table 1). Standard error of a mean (SEM) was used in order to include the cohort size into the calculation of deviations, where SEM represents the standard deviation divided by the square root of the sample number. With the purpose to exhibit both parameters, i.e. percentages of positive cells and staining intensity at once, we have multiplied both parameters. No staining scored zero while low to strong expression obtained values from 1 to 3. Accordingly, maximal resulting score is 300. The mean scores and SEM for CD44s and CD44v6 in normal mucosa of the head and neck were 249.5+/-14.5 and 198+/-11.13 (Fig. 3).
###end p 17
###begin title 18
CD44s expression pattern in head and neck epithelia.
###end title 18
###begin p 19
###xml 135 142 135 142 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in situ</italic>
CD44 standard form was visualised upon immunohistochemistry (reddish brown) in normal epithelium (A), oral leukoplakia (B), carcinomas in situ (C), grade 2 carcinomas (D), and grade 3 carcinomas (E). Cell nuclei are stained with hematoxylin (blue). Shown are representative sections. Arrowheads mark infiltrating lymphocytes with high-level CD44s expression.
###end p 19
###begin title 20
CD44v6 expression pattern in head and neck epithelia.
###end title 20
###begin p 21
###xml 138 145 138 145 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in situ</italic>
CD44 splice variant 6 was visualised upon immunohistochemistry (reddish brown) in normal epithelium (A), oral leukoplakia (B), carcinomas in situ (C), grade 2 carcinomas (D), and grade 3 carcinomas (E). Cell nuclei are stained with hematoxylin (blue). Shown are representative sections.
###end p 21
###begin title 22
CD44s and CD44v6 expression scores in head and neck epithelia.
###end title 22
###begin p 23
###xml 330 332 330 332 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">NE</italic>
###xml 353 355 353 355 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">LP</italic>
###xml 370 373 370 373 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CIS</italic>
###xml 385 392 385 392 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in situ</italic>
###xml 394 399 394 399 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Ca-G2</italic>
###xml 420 425 420 425 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Ca-G3</italic>
The expression scores of CD44s (upper) and CD44v6 (lower) implement expression intensity and percentages of positive cells (score = staining intensityx% positive cells; max score 300). Shown are the mean scores with standard deviations. Where indicated, differences across specimen groups were significant (* p<0.05; ** p<0.005). NE: normal epithelium; LP: leukoplakia; CIS: carcinoma in situ; Ca-G2: grade 2 carcinoma; Ca-G3: grade 3 carcinoma.
###end p 23
###begin title 24
###xml 80 87 80 87 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in situ</italic>
CD44s and CD44v6 expression in normal epithelia (NE), carcinoma (CA), carcinoma in situ (CIS), and leukoplakia (LP).
###end title 24
###begin p 25
- no staining; + weak; ++ moderate; +++ strong.
###end p 25
###begin p 26
The score incorporates the percentage of cells expressing the given antigen multiplied by the staining intensity (0-3). Grading is according to UICC convention.
###end p 26
###begin title 27
CD44 in head and neck epithelia: oral leukoplakia
###end title 27
###begin p 28
###xml 65 72 65 72 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in situ</italic>
###xml 159 163 159 163 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003360-Reichart1">[22]</xref>
###xml 415 423 415 423 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0003360-g001">Figs. 1B</xref>
###xml 428 430 428 430 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0003360-g002">2B</xref>
###xml 530 537 530 537 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pone-0003360-t001">Table 1</xref>
###xml 931 937 923 929 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0003360-g003">Fig. 3</xref>
Oral leukoplakias are at increased risk to progress to carcinoma in situ and full-blown carcinomas or may even already display features of cell transformation [22]. Very much in analogy to normal mucosa, expression of CD44s and CD44v6 in leukoplakias was strongest in cells of the basal membrane layer. With increasing differentiation towards cells of the suprabasal layers, expression of both molecules decreased (Figs. 1B and 2B). CD44s and CD44v6 staining intensity was strong in every one of the leukoplakias tested (n = 22) (Table 1). The percentages of cells that expressed CD44s and CD44v6 were between 50-100% for both proteins (Mean and SEM-CD44s: 93%+/-2.38%; CD44v6: 81%+/-3.94%). The mean scores with SEM for CD44s and CD44v6 in oral leukoplakia were 278.9+/-7.16 and 242+/-11.7, respectively. The increase in CD44s and CD44v6 expression scores in leukoplakia as compared with normal mucosa was considered significant (Fig. 3) (p-value = 0.05 and 0.03, respectively). As mirrored by the increased percentages of staining, expression of both proteins covered more suprabasal cell layers, as compared to normal mucosa.
###end p 28
###begin title 29
CD44 in head and neck epithelia: squamous cell carcinomas
###end title 29
###begin p 30
###xml 99 106 99 106 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in situ</italic>
###xml 222 229 218 225 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pone-0003360-t001">Table 1</xref>
###xml 313 319 305 311 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0003360-g003">Fig. 3</xref>
###xml 741 749 733 741 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0003360-g001">Figs. 1D</xref>
###xml 754 756 746 748 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0003360-g002">2D</xref>
###xml 758 765 750 757 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pone-0003360-t001">Table 1</xref>
###xml 971 977 957 963 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0003360-g003">Fig. 3</xref>
Next, we analysed the expression of CD44s and CD44v6 in head and neck malignancies. Two carcinomas in situ (CIS) stained moderately to strongly with an average and SEM of 100%+/-0% and 95%+/-4.95% of cells being positive (Table 1) and yielding scores with SEM of 250+/-49.9 and 212.5+/-12.5 for CD44s and CD44v6 (Fig. 3). Hence, scores of CIS were comparable to those of normal mucosa and differences across the sample cohort considered not significant. In head and neck carcinomas, which have been classified by two pathologists as moderately differentiated (G2), all cells (100%) except for two sample (80% and 90%) expressed CD44s and CD44v6 to high levels (+++).Only one sample showed a moderate to strong expression (++/+++) of CD44v6 (Figs. 1D and 2D; Table 1). Average percentages with SEM were 97%+/-1.9 for CD44s and for CD44v6. Mean scores with SEM for CD44s and CD44v6 were 291.8+/-5.88 and 287.3+/-6.88 and both were significantly higher than healthy mucosa (Fig. 3).
###end p 30
###begin p 31
###xml 332 340 332 340 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0003360-g001">Figs. 1E</xref>
###xml 345 347 345 347 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0003360-g002">2E</xref>
###xml 349 356 349 356 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pone-0003360-t001">Table 1</xref>
###xml 534 542 530 538 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0003360-g003">Figure 3</xref>
For the case of carcinomas diagnosed as poorly differentiated (G3) staining of CD44s and CD44v6 was characterised by a higher inter-tumour heterogeneity. In other words, percentages of positive cells varied from 60%-100% for both proteins and expression levels ranged from negative (-), weak (+), and moderate (++) to strong (+++) (Figs. 1E and 2E; Table 1). These differences as compared to G2 graded carcinomas were also reflected by significantly lower scores along with higher SEMs (208.8+/-16.68 and 168.8+/-20.6, respectively). Figure 3 shows additional changes in expression scores that were considered significant or highly significant.
###end p 31
###begin title 32
CD44 in lymphoid cells
###end title 32
###begin p 33
###xml 167 170 167 170 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003360-Ponta1">[3]</xref>
###xml 200 209 200 209 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0003360-g001">Figures 1</xref>
###xml 214 215 214 215 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0003360-g004">4</xref>
###xml 427 434 427 434 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0003360-g001">Figs. 1</xref>
###xml 439 440 439 440 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0003360-g004">4</xref>
###xml 599 606 599 606 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0003360-g002">Figs. 2</xref>
###xml 611 612 611 612 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0003360-g004">4</xref>
###xml 1026 1033 1026 1033 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0003360-g004">Fig. 4A</xref>
###xml 1228 1235 1228 1235 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0003360-g004">Fig. 4A</xref>
###xml 1399 1406 1399 1406 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0003360-g004">Fig. 4B</xref>
###xml 1520 1527 1520 1527 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0003360-g004">Fig. 4B</xref>
###xml 1664 1671 1664 1671 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0003360-g004">Fig. 4B</xref>
###xml 1874 1881 1874 1881 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0003360-g005">Fig. 5A</xref>
###xml 1989 1993 1989 1993 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003360-Wiesner1">[23]</xref>
###xml 2062 2069 2062 2069 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0003360-g005">Fig. 5B</xref>
###xml 2219 2226 2219 2226 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0003360-g005">Fig. 5C</xref>
###xml 2304 2308 2304 2308 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003360-Pries1">[14]</xref>
###xml 2328 2335 2328 2335 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0003360-g005">Fig. 5D</xref>
###xml 1904 1909 <span type="species:ncbi:9606">human</span>
###xml 2087 2105 <span type="species:ncbi:10376">Epstein-Barr virus</span>
CD44s has been initially described in lymphocytes while CD44v6 was described as being expressed more specifically in epithelia and, more precisely, in tumours thereof [3]. It could already be seen in Figures 1 and 4 that CD44s was not solely expressed in epithelia in head and neck tumour specimens. Rather was CD44s also strongly present at the plasma membrane of lymphocytic cells and was loosely stained in the stroma, too (Figs. 1 and 4, and data not shown). Much in contrast to this, CD44v6 was exclusively expressed on epithelial cells although massive lymphoid infiltrates could be detected (Figs. 2 and 4). For this reason, we compared CD44s and CD44v6 staining directly in consecutive serial sections of the same samples. In one case of CIS, microscopically healthy mucosa was in close proximity of CIS cells and separated by interstitial lymphocytes. This specific case was chosen for comparison of CD44s and CD44v6 expression. CD44v6 was strictly detected in epithelial cells in the normal mucosa and in CIS cells (Fig. 4A right panel). Lymphocytic cells lining vessels and the CIS were devoid of CD44v6. In sharp contrast, CD44s was present in CIS and normal epithelium, but likewise in infiltrating lymphoid cells (Fig. 4A, left panel). The same situation was encountered in HNSCC, where CD44v6 discriminated between carcinoma cells (positive), stroma and lymphocytic cells (negative) (Fig. 4B, right panel). Oppositely, CD44s was present in carcinoma cells and in infiltrating cells to even higher levels (Fig. 4B, left panel). Only exceptions were areas of horn-pearl forming and keratinising tumour cells, which hardly stained for CD44s or CD44v6 (Fig. 4B). These findings were further substantiated upon staining of peripheral blood mononuclear cells. CD44s but not CD44v6 was expressed on cells of the lymphocytic gate and the monocytic/granulocytic gate (Fig. 5A). B blasts, which are human B cells that have been conditionally immortalised upon permanent CD40 ligation [23], expressed CD44s to substantial amounts but entirely lacked CD44v6 (Fig. 5B). Interestingly, Epstein-Barr virus transformed lymphoblastoid cell lines (LCLs) expressed large amounts of CD44s and to varying extent also CD44v6 (Fig. 5C). HNSCC FaDu cells also strongly expressed CD44s, as was described elsewhere [14], and lacked CD44v6 Fig. 5D.
###end p 33
###begin title 34
Comparative expression of CD44s and CD44v6 in head and neck epithelia.
###end title 34
###begin p 35
###xml 95 102 95 102 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in situ</italic>
###xml 179 182 179 182 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CIS</italic>
###xml 194 201 194 201 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in situ</italic>
###xml 203 205 203 205 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ve</italic>
###xml 215 218 215 218 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">muc</italic>
###xml 228 231 228 231 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">int</italic>
###xml 247 249 247 249 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ca</italic>
###xml 262 264 262 264 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">HP</italic>
CD44s and CD44v6 (reddish brown) were visualised in consecutive serial sections of a carcinoma in situ (A) and one carcinoma (B). Cell nuclei are stained with hematoxylin (blue). CIS: carcinoma in situ; ve: vessel; muc: mucosa; int: interstitium; ca: carcinoma; HP: horn-pearl forming keratinised tumour cells. Shown are representative sections.
###end p 35
###begin title 36
Comparative expression of CD44s and CD44v6 in lymphoid cells.
###end title 36
###begin p 37
Cell surface expression of CD44s and CD44v6 were assessed on peripheral blood mononuclear cells (A), B blast clones (B), lymphoblastoid cell clones (C), and HNSCC FaDu cells (D) using specific antibodies and flow cytometry. Red line: control; black line: specific antibody. LCL: lymphoblastoid cell lines. Shown are representative results of two independent measurements.
###end p 37
###begin title 38
Discussion
###end title 38
###begin p 39
###xml 132 148 132 148 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">stochastic model</italic>
###xml 265 283 265 283 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">hierarchical model</italic>
###xml 576 580 576 580 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003360-Cho1">[24]</xref>
###xml 704 711 704 711 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vivo</italic>
###xml 801 807 801 807 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">et al.</italic>
###xml 853 857 853 857 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003360-AlHajj1">[12]</xref>
###xml 887 888 887 888 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 893 894 893 894 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;</sup>
###xml 898 899 898 899 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;</sup>
###xml 905 909 905 909 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">high</sup>
###xml 1011 1018 1011 1018 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vivo</italic>
###xml 1264 1267 1264 1267 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003360-Kuhn1">[5]</xref>
###xml 1340 1344 1340 1344 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003360-Dalerba1">[13]</xref>
###xml 1376 1380 1376 1380 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003360-Baeuerle1">[25]</xref>
###xml 1382 1386 1382 1386 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003360-Gires1">[26]</xref>
###xml 1612 1616 1612 1616 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003360-Pries1">[14]</xref>
###xml 1617 1621 1617 1621 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003360-Prince2">[16]</xref>
###xml 990 995 <span type="species:ncbi:9606">human</span>
###xml 1055 1061 <span type="species:ncbi:10090">murine</span>
It was roughly a decade ago when scientists revisited the view of tumour origination for the case of leukemia. Coming from a rather stochastic model, where every single cell of a tumour would be equipped with tumourigenic potential, scientists moved towards a more hierarchical model, with only a subset of cells within malignant tissue that are able to generate tumours. In this model so-called cancer stem cells, CSCs, are the founders of tumours. CSCs display to some degree properties of normal stem cells including self-renewal, pluripotency, and limitless proliferation [24]. The remaining cancer cells that lack these properties are characterised by a restricted or even no growth capacity at all in vivo. Data supporting the notion of CSCs in solid tumours emerged in early 2000, when Al-Hajj et al. characterised breast cancer-initiating cells [12]. Breast CSCs displayed a CD44+/CD24-/lin-/ESA-1high cell surface phenotype. Amazingly, as few as 100 cells sufficed to recapitulate human carcinogenesis in vivo upon inoculation in immunodeficient murine recipients. Importantly, resulting tumours were of mixed phenotype, included all epithelial cells seen in the primary tumours, and could be serially transplanted. The interacting protein CD44 and EpCAM [5] were part of the CSC signature in not only breast cancer but also colon [13]. With respect to EpCAM (ESA-1) [25], [26], it was consistently the phenotype of high-level expression that characterised CSCs. This was markedly different for CD44, whose simple expression discriminated CSCs from non-tumourigeneic cells in head and neck malignancies [14]-[16].
###end p 39
###begin p 40
###xml 287 291 287 291 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003360-Soukka1">[18]</xref>
###xml 292 296 292 296 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003360-vanHal1">[20]</xref>
###xml 646 652 646 652 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">et al.</italic>
###xml 794 798 794 798 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003360-Prince1">[15]</xref>
###xml 800 804 800 804 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003360-Prince2">[16]</xref>
###xml 1178 1184 1178 1184 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">et al.</italic>
###xml 1353 1357 1353 1357 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003360-Kawano1">[27]</xref>
###xml 678 686 <span type="species:ncbi:9606">patients</span>
###xml 1238 1246 <span type="species:ncbi:9606">patients</span>
In the present study the expression of the standard form CD44s and the tumour-associated alternative splice variant CD44v6 were assessed in epithelia of the head and neck, including pre-malignancies and full-blown carcinomas. Surprisingly and somewhat in contradiction to available data [18]-[20], CD44s was abundantly expressed in most tumour cells within HNSCC. Percentages of CD44s-positive cells in normal head and neck epithelial cells ranged from 60% to 95% with strong staining intensities. In moderately differentiated HNSCC, CD44s was present in 80-100% of tumour cells and additionally in virtually all infiltrating lymphocytes. Prince et al. reported on thirty-three patients suffering from diverse HNSCC including tongue, larynx, floor of the mouth, oropharynx, and maxillary sinus [15], [16]. In these cases CD44s percentages within tumours ranged from 0.1% to 41.72%, hence low levels, and were typically below 10% of the total tumour cell population, which remained unseen in our specimens. It is important to note that the same antibody specific for CD44s was used in both studies and that antibody concentrations used herein were down to 100-fold lower. Kawano et al. on the other hand described that 75.4% of samples of patients suffering from mesopharyngeal cancers (n = 57) were positive for CD44s and 78.9% were positive for CD44v6 [27]. These dimensions fit the percentages of CD44s and CD44v6 expressing cells assessed herein.
###end p 40
###begin p 41
###xml 502 506 502 506 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003360-Marhaba1">[28]</xref>
###xml 508 512 508 512 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003360-Cheng1">[29]</xref>
###xml 616 620 616 620 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003360-Staibano1">[30]</xref>
The alternative splice variant CD44v6 showed an expression pattern similar to CD44s in epithelial areas, independently of the transformation status. We could only detect an over-expression of CD44v6 in grade 2 carcinomas as compared to normal epithelium. However, in contrast to CD44s, CD44v6 was not expressed in infiltrating lymphocytic cells but remained restricted to epithelia. CD44v6 was of interest owing to its potential to increase proliferation via the MAP kinase and Ras signalling pathways [28], [29]. Also, CD44v6 expression was correlated with a reduced disease-free survival in laryngeal malignancies [30]. We could however not confirm a clear association of CD44v6 with malignancy for HNSCC.
###end p 41
###begin p 42
###xml 250 254 250 254 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">i.e.</italic>
###xml 270 276 270 276 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">versus</italic>
###xml 462 466 462 466 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003360-Shmelkov1">[17]</xref>
###xml 477 483 477 483 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">et al.</italic>
###xml 576 580 576 580 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003360-Shmelkov1">[17]</xref>
###xml 675 676 675 676 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 686 687 686 687 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;</sup>
###xml 537 543 <span type="species:ncbi:10090">murine</span>
###xml 548 553 <span type="species:ncbi:9606">human</span>
###xml 751 755 <span type="species:ncbi:10090">mice</span>
In summary, we show that CD44s is abundantly expressed in head and neck carcinomas. This is in sharp contrast to previous reports on CD44s and cancer stem cells in HNSCC, and may rely on different technologies used to visualise CD44s-positive cells, i.e. flow cytometry versus immunohistochemistry. Similar inconsistencies have been reported recently concerning CD133, a marker for CSCs in numerous entities including colon, brain, prostate, liver, and pancreas [17]. Shmelkov et al. demonstrated that CD133 is ubiquitously expressed in murine and human colon carcinoma cells [17]. Further on cancer stem cell potential was not restricted to CD133-positive cells. Both, CD133+ and CD133- cells bore long-term tumourigenic potential in immunodeficient mice. Though the principle and existence of CSCs remains undoubted, the actual nature of markers of tumour-initiating cells, their usage, expression, and signification need more attention.
###end p 42
###begin title 43
Materials and Methods
###end title 43
###begin title 44
Tissue samples
###end title 44
###begin p 45
###xml 73 80 73 80 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in situ</italic>
###xml 362 446 362 446 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Ethikkommision der Medizinischen Fakult&#228;t der Ludwig-Maximilians-Universit&#228;t M&#252;nchen</italic>
###xml 773 782 772 781 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="pone.0003360.s002">Figure S2</xref>
Samples of normal mucosa (n = 10), oral leukoplakia (n = 22), carcinomas in situ (CIS) (n = 2), moderately differentiated carcinomas (G2; n = 11), and poorly differentiated carcinomas (G3; n = 13) were obtained after written informed consent during routine surgery according to institutional ethics approval by the ethics committee of the local medical faculty (Ethikkommision der Medizinischen Fakultat der Ludwig-Maximilians-Universitat Munchen). All samples were embedded in tissue-tek (Sakura, Fintek, NL) and snap-frozen in liquid nitrogen before processing to 4mum thick consecutive cryosections. All specimens had been examined and confirmed by two pathologists during routine clinical diagnosis and histopathologic examination after hematoxylin/eosin staining (see Figure S2 for examples of H/E staining).
###end p 45
###begin title 46
Immunohistochemistry
###end title 46
###begin p 47
###xml 499 500 499 500 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 501 502 501 502 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 1027 1028 1027 1028 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 1029 1030 1029 1030 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 4 9 <span type="species:ncbi:10090">mouse</span>
###xml 15 20 <span type="species:ncbi:9606">human</span>
###xml 28 33 <span type="species:ncbi:10090">mouse</span>
###xml 99 104 <span type="species:ncbi:9606">human</span>
###xml 113 118 <span type="species:ncbi:10090">mouse</span>
###xml 595 600 <span type="species:ncbi:9796">horse</span>
###xml 756 761 <span type="species:ncbi:10090">mouse</span>
###xml 1191 1196 <span type="species:ncbi:10090">mouse</span>
The mouse anti-human CD44s (mouse IgG2b, lot # 86572, BD Pharmingen, Heidelberg, Germany) and anti-human CD44v6 (mouse IgG1, lot # 212115, Novocastra, New Castle upon Tyne, UK) primary antibodies were used. Immunostaining was performed using the avidin-biotin-peroxidase complex method (Vectastain, Vector laboratories, Burlingame, CA, USA) according to the manufacturers protocol. Briefly, after fixation in acetone (10 min), endogenous peroxidase activity was inhibited upon treatment with 0.03% H2O2/PBS (10 min). Before specific staining, unspecific antigenic sites were blocked with normal horse serum. Sections were then incubated with the respective primary antibody for 1 hour at room temperature (RT) followed by incubation with biotinylated anti-mouse immunoglobulins and then with avidin-biotin-peroxidase complex (30 minutes at RT for each step). After each step, sections were washed with PBS. Specific peroxidase activity was visualized with 0.05% 3-amino-9-ethylcarbazol (Sigma, Deisenhofen, Germany) and 0.02% H2O2/0,1M Na-acetat buffer pH5.5 as a substrate. Counterstaining was performed with Mayers hematoxylin and eosin. As a negative control, staining was performed with mouse pre-immune serum instead of specific antibodies. Assessment of percentages of positive cells was performed across the entire sample in a blinded fashion upon light microscopy by two investigators and is given as the mean of both percentages assessed in steps of 5%.Percentages of staining refer to epithelial/tumour cells within samples.
###end p 47
###begin title 48
Flow cytometry
###end title 48
###begin p 49
###xml 223 228 <span type="species:ncbi:10090">mouse</span>
Peripheral blood mononuclear cells, B blasts, lymphoblastoid cell lines, or head and neck squamous cell carcinoma cells FaDu were stained with CD44s- or CD44v6-specific antibodies in combination with a FITC-conjugated anti-mouse secondary antibody. Fluorescence intensities were assessed after washing in PBS in a FACScalibur device (Becton Dickinson, Heidelberg, Germany).
###end p 49
###begin title 50
Supporting Information
###end title 50
###begin p 51
Hematoxylin/eosin staining was performed on kryosection of normal epithelium, carcinoma in situ, grades 2 and 3 carcinomas. Stained samples were examined by two pathologists and different areas within specimens were denoted. Shown are representative examples of the entire cohort used in the present study.
###end p 51
###begin p 52
(4.16 MB TIF)
###end p 52
###begin p 53
Click here for additional data file.
###end p 53
###begin p 54
###xml 98 104 <span type="species:ncbi:10090">murine</span>
Negative controls for immunohistochemistry. Normal mucosa and grade 2 carcinoma were stained with murine pre-immune serum in combination with standardised detection systems. Nuclei were counter-stained with hematoxylin. Shown are representative results from the cohort analysed in the present study.
###end p 54
###begin p 55
(1.57 MB TIF)
###end p 55
###begin p 56
Click here for additional data file.
###end p 56
###begin p 57
The authors whish to thank Dr. Andreas Moosmann for the kind supply with PBMCs, LCLs, and B blasts.
###end p 57
###begin title 58
References
###end title 58
###begin article-title 59
CD44 is the principal cell surface receptor for hyaluronate.
###end article-title 59
###begin article-title 60
Involvement of CD44, a molecule with a thousand faces, in cancer dissemination.
###end article-title 60
###begin article-title 61
CD44: from adhesion molecules to signalling regulators.
###end article-title 61
###begin article-title 62
###xml 73 79 <span type="species:ncbi:10090">murine</span>
Biochemical characterization and cellular distribution of a polymorphic, murine cell-surface glycoprotein expressed on lymphoid tissues.
###end article-title 62
###begin article-title 63
A complex of EpCAM, claudin-7, CD44 variant isoforms, and tetraspanins promotes colorectal cancer progression.
###end article-title 63
###begin article-title 64
###xml 67 70 <span type="species:ncbi:10116">rat</span>
A new variant of glycoprotein CD44 confers metastatic potential to rat carcinoma cells.
###end article-title 64
###begin article-title 65
Regulated CD44 cleavage under the control of protein kinase C, calcium influx, and the Rho family of small G proteins.
###end article-title 65
###begin article-title 66
Presenilin-dependent intramembrane proteolysis of CD44 leads to the liberation of its intracellular domain and the secretion of an Abeta-like peptide.
###end article-title 66
###begin article-title 67
Cell-matrix interaction via CD44 is independently regulated by different metalloproteinases activated in response to extracellular Ca(2+) influx and PKC activation.
###end article-title 67
###begin article-title 68
Mechanism and biological significance of CD44 cleavage.
###end article-title 68
###begin article-title 69
Proteolytic release of CD44 intracellular domain and its role in the CD44 signaling pathway.
###end article-title 69
###begin article-title 70
Prospective identification of tumorigenic breast cancer cells.
###end article-title 70
###begin article-title 71
###xml 31 36 <span type="species:ncbi:9606">human</span>
Phenotypic characterization of human colorectal cancer stem cells.
###end article-title 71
###begin article-title 72
Potential stem cell marker CD44 is constitutively expressed in permanent cell lines of head and neck cancer.
###end article-title 72
###begin article-title 73
Identification of a subpopulation of cells with cancer stem cell properties in head and neck squamous cell carcinoma.
###end article-title 73
###begin article-title 74
Cancer stem cells in head and neck squamous cell cancer.
###end article-title 74
###begin article-title 75
CD133 expression is not restricted to stem cells, and both CD133 and CD133 metastatic colon cancer cells initiate tumors.
###end article-title 75
###begin article-title 76
Regulation of CD44v6-containing isoforms during proliferation of normal and malignant epithelial cells.
###end article-title 76
###begin article-title 77
Expression of CD44 splice variants in squamous epithelia and squamous cell carcinomas of the head and neck.
###end article-title 77
###begin article-title 78
Characterization of CD44v6 isoforms in head-and-neck squamous-cell carcinoma.
###end article-title 78
###begin article-title 79
Evaluation of soluble CD44v6 as a potential serum marker for head and neck squamous cell carcinoma.
###end article-title 79
###begin article-title 80
Oral erythroplakia-a review.
###end article-title 80
###begin article-title 81
###xml 31 36 <span type="species:ncbi:9606">human</span>
Conditional immortalization of human B cells by CD40 ligation.
###end article-title 81
###begin article-title 82
Recent advances in cancer stem cells.
###end article-title 82
###begin article-title 83
EpCAM (CD326) finding its role in cancer.
###end article-title 83
###begin article-title 84
TACSTD1 (tumor-associated calcium signal transducer 1).
###end article-title 84
###begin article-title 85
Expression of E-cadherin, and CD44s and CD44v6 and its association with prognosis in head and neck cancer.
###end article-title 85
###begin article-title 86
CD44v6 promotes proliferation by persisting activation of MAP kinases.
###end article-title 86
###begin article-title 87
A positive feedback loop couples Ras activation and CD44 alternative splicing.
###end article-title 87
###begin article-title 88
OPN/CD44v6 overexpression in laryngeal dysplasia and correlation with clinical outcome.
###end article-title 88
###begin p 89
###xml 0 21 0 21 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Competing Interests: </bold>
Competing Interests: The authors have declared that no competing interests exist.
###end p 89
###begin p 90
###xml 0 9 0 9 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Funding: </bold>
Funding: The authors have no support or funding to report.
###end p 90

